Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DNA Vaccines
Researchers at Urmia University of Medical Sciences target DNA vaccines
March 11th, 2009
Researchers detail in 'A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine,' new data in dna. "While many adjuvants have been discovered and used in research, only a few adjuvants have been permitted for use with human vaccination. We have previously shown that the administration of naloxone (NLX), a general opioid antagonist, during infection with a non-virulent strain of herpes simplex virus type 1 (HSV-1) could enhance protection against HSV-1 challenge," researchers in Iran report. "Here, the adjuvant activity of NLX has been evaluated using a DNA vaccine for HSV-1 as a model. BALB/c mice were divided...
Source: Vaccine Weekly (2009-03-11)
|
